Charles River Laboratories International, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 4, 2026, covering the fiscal quarter ended September 26, 2026.
Key Highlights
- Shares outstanding: As of October 24, 2026, the company reported 47,917,467 shares of common stock outstanding.
- Filing period: The quarterly report covers the three and nine months ended September 26, 2026, with comparative periods ended September 27, 2025.
- Large accelerated filer: Charles River Laboratories is classified as a large accelerated filer under the Exchange Act definitions, according to the filing.
- Pending legal matters: The filing references three ongoing lawsuits, including a putative securities class action filed May 19, 2023, and two derivative lawsuits filed November 8, 2023 and August 2, 2024, respectively.
- Non-human primate supply: The filing identifies NHP availability and supply chain diversification as a topic addressed by forward-looking statements in the report.
- No shell company status: The registrant confirmed it is not a shell company as defined under Rule 12b-2 of the Exchange Act.
Charles River Laboratories Reports Third Quarter 2026 Filing Details
Charles River Laboratories International, Inc. (NYSE:CRL), a Delaware-incorporated contract research and preclinical services organization headquartered at 251 Ballardvale Street, Wilmington, Massachusetts, filed its Form 10-Q for the quarter ended September 26, 2026, on November 4, 2026. According to the filing, the company had 47,917,467 shares of common stock outstanding as of October 24, 2026. The registrant holds Commission File No. 001-15943 and confirmed that it has filed all required Exchange Act reports during the preceding 12 months.
The filing covers unaudited condensed consolidated financial statements for the three and nine months ended September 26, 2026, compared to the equivalent periods ended September 27, 2025. The report includes condensed consolidated statements of income, comprehensive income, balance sheets, cash flows, and changes in equity and redeemable noncontrolling interests, the company disclosed. Management's Discussion and Analysis sections covering results of operations, liquidity and capital resources, and critical accounting policies are also included, according to the table of contents.
The filing identifies several areas subject to forward-looking statements, including the company's expectations regarding non-human primate sourcing, client demand for drug discovery and development services, stock repurchase activity, restructuring actions under the company's "Create the Future" program, and the outcome of three pending legal proceedings. The company cautioned that "actual results may differ materially and adversely from those expressed in any forward-looking statements," and directed readers to the 2025 Annual Report on Form 10-K for additional risk factor disclosures.
What Was Disclosed
Charles River Laboratories International, Inc. submitted its Form 10-Q for the fiscal quarter ended September 26, 2026, reporting 47,917,467 shares outstanding as of October 24, 2026, and confirming its status as a large accelerated filer with ongoing legal proceedings and forward-looking disclosures on NHP supply and business operations.


Please wait processing your request...